Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Browsing Tag

weight management

9 posts
RRoche
Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Read More

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

  • 2026-06-08
F. Hoffmann-La Roche Ltd Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to…
RRoche
Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Read More

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

  • 2026-06-01
F. Hoffmann-La Roche Ltd Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to…
RRoche
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
Read More

Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management

  • 2026-05-14
Zealand Pharma Company announcement – No. 11 / 2026 Zealand Pharma and Roche to advance petrelintide, an amylin…
RRoche
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
Read More

Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management

  • 2026-05-03
Zealand Pharma Company announcement – No. 11 / 2026 Zealand Pharma and Roche to advance petrelintide, an amylin…
RRoche
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
Read More

Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity

  • 2026-03-08
F. Hoffmann-La Roche Ltd Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7%…
RRoche
Roche Reports Upbeat Efficacy Data From Phase II Obesity Study
Read More

Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal

  • 2026-03-07
Roche RHHBY has announced that the mid-stage study ZUPREME-1, evaluating the investigational candidate petrelintide for the treatment of…
RRoche
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
Read More

Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity

  • 2026-03-06
F. Hoffmann-La Roche Ltd Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7%…
RRoche
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
Read More

Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity

  • 2026-03-05
F. Hoffmann-La Roche Ltd Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7%…
RRoche
Examining Valuation After Recent Share Price Momentum
Read More

Roche’s CT-388 Obesity Data Tests New Growth Pillar Potential

  • 2026-02-16
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…
Switzerland
www.europesays.com